Mass Immunization Device
Search text
No Name Given Kanhaiya
1 result
(0.02 seconds)
University of Pittsburgh researchers have developed a novel approach to augment VEGF therapy for ischemic tissue revascularization using epigenetic principles. Researchers identified that hyperglycemia leads to DNA methylation-based silencing of the PLCγ2 gene, hindering VEGF therapy. Using a CRISPR/dCas9-based demethylation cocktail delivered via tissue nano-transfection (TNT) technology, the PLCγ2 promoter is specifically demethylated in endothelial cells during VEGF therapy.